Exelixis (EXEL) Competitors

Exelixis (NASDAQ:EXEL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership.

Does the MarketBeat Community prefer EXEL or ALNY?

Alnylam Pharmaceuticals received 540 more outperform votes than Exelixis when rated by MarketBeat users. Likewise, 76.32% of users gave Alnylam Pharmaceuticals an outperform vote while only 68.52% of users gave Exelixis an outperform vote.

Company	Underperform	Outperform
Exelixis	Outperform Votes 627 68.52%	Underperform Votes 288 31.48%
Alnylam Pharmaceuticals	Outperform Votes 1167 76.32%	Underperform Votes 362 23.68%

Do institutionals and insiders believe in EXEL or ALNY?

85.3% of Exelixis shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 2.8% of Exelixis shares are held by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is EXEL or ALNY more profitable?

Exelixis has a net margin of 24.04% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Exelixis' return on equity of 23.52% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	24.04%	23.52%	17.95%
Alnylam Pharmaceuticals	-12.37%	N/A	-6.83%

Which has better earnings and valuation, EXEL or ALNY?

Exelixis has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.30B	5.09	$521.27M	$2.20	19.52
Alnylam Pharmaceuticals	$2.35B	16.87	-$278.16M	-$2.09	-145.32

Which has more volatility & risk, EXEL or ALNY?

Exelixis has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500.

Does the media favor EXEL or ALNY?

In the previous week, Exelixis had 3 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 28 mentions for Exelixis and 25 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.92 beat Exelixis' score of 0.85 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	14 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	17 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer EXEL or ALNY?

Exelixis currently has a consensus price target of $39.35, indicating a potential downside of 8.34%. Alnylam Pharmaceuticals has a consensus price target of $319.17, indicating a potential upside of 5.09%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.47
Alnylam Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Exelixis and Alnylam Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.